Market Overview

Opexa Therapeutics Prices ~1.083M Units at $3/Unit

Related OPXA
Stocks Hitting 52-Week Lows
Morning Market Losers

Opexa Therapeutics, Inc. (NASDAQ: OPXA) a company developing Tcelna™ (imilecleucel-T), a novel T-cell therapy for multiple sclerosis (MS), today announced it has priced an offering of shares of its common stock and warrants to purchase common stock in a private registered offering of 1,083,334 units at a price of $3.00 per unit, for gross proceeds of $3,250,000. Each unit consists of one share of common stock and a warrant to purchase one-half (0.50) of a share of common stock. The shares of common stock and warrants are immediately separable and will be issued separately such that no units will be issued. The warrants are exercisable immediately upon issuance, have a four-year term and an exercise price of $3.00 per share. The offering is expected to close on or about February 11, 2013, subject to customary closing conditions. All of the shares in the offering are to be sold by Opexa.

The net proceeds from these financing arrangements will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's ongoing Phase 2b clinical trial of Tcelna in Secondary Progressive MS patients.

Posted-In: News Offerings

 

Related Articles (OPXA)

Around the Web, We're Loving...

Get Benzinga's Newsletters